surmount-1 tirzepatide weight loss percent nejm 2022 In the trial (published in in July 2022), adults with #obesity treated with weekly tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor Retatrutide Phase 2 NEJM Trial:
Description
The needle guard should slide into place on its own
At 10 mg/mL, 50 units delivers 5 mg, which is double her prescribed starting dose
The medication is administered as a once-weekly injection and works best when combined with lifestyle changes, such as healthy eating, increased physical activity, and behavioral supportall services that we help coordinate at Centra Internal Medicine
The observed effects were consistent in all investigated subgroups, with a trend toward stronger effects in subjects with T2D and higher cardiovascular risk (77)
In my head I had this magical number of like 110 or something ludicrous I wanted to weigh..maybe 125
In the SURMOUNT-1 clinical trial, participants on the highest dose of tirzepatide lost an average of 22.5% of their body weight over 72 weeks
